



JOHNS HOPKINS
M E D I C I N E

From Evidence to Action: Bridging Gaps in Lipid Management Using Digital Technology & Telehealth

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC
Professor of Medicine, Division of Cardiology
Johns Hopkins University School of Medicine
Director, Ciccarone Advanced Lipid Disorders Clinic
Director, Digital Health Innovations Lab
Barker Firm Faculty Leader, Osler Medical Residency

AHA Scientific Sessions 2025

Disclosures

- Johns Hopkins University previously filed a patent for the Martin/Hopkins LDL-C calculation and has since abandoned the patent to enable widespread adoption
- Co-Founder, Corrie Health, a digital health startup powering preventive CV care
- Philanthropic support from David & June Trone Foundation, Pollin Digital Innovation Fund, PJ Schafer Cardiovascular Research Fund, Sandra and Larry Small
- Research support from the American Heart Association (20SFRN35380046, 20SFRN35490003, COVID19-811000, AHA878924, AHA882415, AHA946222), PCORI (ME-2019C1-15328, IHS-2021C3-24147), NIH (P01 HL108800, R01AG071032), Aetna Foundation, Maryland Innovation Initiative, Amgen, Google, Apple, and Merck
- Consulting for Amgen, Arrowhead, AstraZeneca, BMS, Chroma, HeartFlow, Kaneka, Merck, NewAmsterdam, Novartis, Pfizer, Sanofi, Verve Therapeutics




Objectives

- 1) Explores the potential of a patient-facing technology designed to enhance lipid management and cardiovascular outcomes through dynamic education, patient engagement, and clinical decision support
- 2) Discuss improvements in workflow for telehealth patient visits to enhance program success by providing accessible, real-time support and personalized guidance to patients as they achieve their LDL cholesterol goals



Activating Patients in Using Digital Health After Acute Myocardial Infarction

corrie  **Clinical Trial**
Clinical Evidence Supporting Readmission Reduction



SOURCES:
Circ Cardiovasc Qual Outcomes. 2021 Jul;14(7):e007741.
Medical Care. 2021 Nov 1;59(11):1023-1030.

Corrie Health Lipids Program


A Digitally Powered Implementation Program to Optimize LDL-C



Allison Peng
Lipids Program Fellow
apeng4@jh.edu



Enrolling Now



1000 Patients

- Known ASCVD or high risk ASCVD

3 US Study Sites

- Johns Hopkins, Yale, Penn State

Corrie Lipids Program

- Enrollment with Corrie App
- LLT intensified to achieve guideline-based LDL-C levels

Outcomes

- LDL-C control at the end 6 months
- RE-AIM findings (Reach, Effectiveness, Adoption, Implementation, and Maintenance)



Corrie Lipids Technology

< Back Evolocumab (Repatha) Edit

This Week Overall

100%

DOSAGE

140 mg

Lowers bad cholesterol to prevent heart attacks and strokes.

TIME TO TAKE MEDICATION

Dose 1: 8:00 AM

WHAT IT DOES

Lowers bad cholesterol to prevent heart attacks and strokes.

SIDE EFFECTS

Side effects are uncommon.

Tasks Vitals ABCs Check Up Connect

< Labs Measurement

Please Enter Your Bad Cholesterol

32 mg/dL

Save

1 2 3
4 5 6
7 8 9
0

< Check Up Labs

LDL cholesterol
Lab data

32 mg/dL

70 mg/dL

Enter new value

See history

Tasks Vitals ABCs Check Up Connect

< Labs LDL cholesterol

97 mg/dL 02/01/24

98 mg/dL 01/02/24

92 mg/dL 02/02/24

32 mg/dL 11/03/24

Tasks Vitals ABCs Check Up Connect

< Cholesterol 101 Speak



If you have had a heart attack, your goal LDL cholesterol is less than 70 mg/dL. Ideally it will be less than 50 mg/dL. If your cholesterol values are higher, then you are at a higher risk for heart disease.

Typical goal LDL cholesterol



Less than 70 mg/dL

medications you may be given are Zetia and/or a PCSK9 inhibitor.


Tasks Vitals ABCs Check Up Connect

Program Eligibility for Corrie Lipids

Identifying and engaging **clinicians** and their **high-risk patients** who have an indication for LLT intensification to achieve optimal LDL-C levels (<70 or <55 mg/dL for secondary prevention, <100mg/dL for primary prevention)



Enrollment and Clinical Workflow



1. Multiple Enrollment Channels:


Community, social media, clinician referral (SlicerDicer)

2. **Access:** Patients receive email-based invitations to download Corrie App

3. **Awareness:** Patients receive education through Corrie App on LDL-C, clinicians have virtual training

4. **Achievement:** By providing Corrie app, guideline-based LDL-C testing, and Advanced Lipid consultative services

Patient-Centered Support From Centralized, Remote Team to Improve Telehealth Workflow



Status	Notificati...
 Checked Out Checked out: 10:43 AM	
 Checked Out Checked out: 11:45 AM	
 Checked Out Checked out: 12:59 PM	
 Checked Out Checked out: 1:54 PM	
 Visit in Progress Checked in: 1:52 PM	
 Arrived Checked in: 2:13 PM	
 Visit in Progress Checked in: 2:09 PM	

Scaling LDL-C Awareness, Access, and Achievement



Scalable technology

The Corrie platform is capable of reaching millions of users based on a scalable and adaptive technology architecture



Trust and Credibility


Corrie has strong partnerships with Johns Hopkins, Apple, American Heart Association, and American College of Cardiology



Digital Health Experience

Corrie health has worked with patients across health systems with the mission of optimal heart health awareness, access, and achievement

The Digital Powered Future of Lipid Management and Cardiovascular Care



Summary

- The AHA Telehealth Network collaborative is sharing learnings to improve access to telehealth and digital tools
- Corrie Lipids is a unique and ambitious digital health program designed to close gaps in LDL-C management through the power of protocols and patient activation
- Alongside digital apps, patient-centered support from a centralized, remote team may be an efficient and effective approach to improve care delivery

Thank You